Advanced Cancer Pain

Title: A double-blind, randomized, placebo-controlled, parallel-group, dose-range exploration study of Sativex^® in relieving pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy.

Institutional Review Board: Sterling Institutional Review Board

Status: Closed

Phase: 2

Purpose: To determine the effective and demonstrate the noneffective dose range of Sativex^® in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy.

Eligibility:

• Patients with advanced cancer for which there is no known curative therapy
• Patients with a clinical diagnosis of cancer-related pain that is no completely alleviated with their opioid treatment

Duration: 4 visits over 9 weeks, including a first visit for a baseline assessment, visit 2 for randomization, visit 3 at day 22, and visit 4 for end of treatment.

Prinicipal Investigator: Michael B. Wax, MD

Contact: Isabella Rodrigues, PhD
Clinical Research Coordinator

Genevieve Barragan, BA
Clinical Research Coordinator